SA17 ON-DEMAND TREATMENTS FOR HEREDITARY ANGIOEDEMA AND HEALTHCARE RESOURCE UTILIZATION IN PEDIATRIC (2-11 YEARS) PATIENTS: A US CLAIMS DATABASE ANALYSIS
Raffi Tachdjian(University of California, Los Angeles), Alice Wang(KalVista Pharmaceuticals (United States)), Héloïse Reumaux(Hôpital Jeanne de Flandre), Paul Audhya(Reata Pharmaceuticals (United States)), Adil Adatia(University of Alberta), Emel Aygören‐Pürsün, Aharon Kessel(Technion – Israel Institute of Technology), Bob Geng(Rady Children's Hospital-San Diego), Aditya Sehgal(Government of Haryana), H. Henry Li(Institute for Asthma and Allergy), H. James Wedner(Washington University in St. Louis), Mauro Cancian(University of Padua)
Cited by 0
Related Papers
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients
|Allergy|2004|301
Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells
|Autoimmunity Reviews|2011|293
Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function
|The Journal of Immunology|2007|229